CollaborationOsivax and GC Biopharma partner on broader flu vaccineFrench biotech Osivax and South Korea-based GC Biopharma have partnered to develop a seasonal influenza vaccine combining Osivax’s broad-spectrum OVX836 candidate with GC Biopharma’s marketed GC … more ➔
Financing RoundRedx raises $36M to fund Phase 2 Crohn’s disease trialUK-based Redx Pharma has closed a $36 million (€31 million) Series A financing round to support a Phase 2 trial of its Crohn’s disease drug candidate. more ➔
Infectious diseaseBerlin-developed Ebola vaccine heads toward African trialThe Coalition for Epidemic Preparedness Innovations (CEPI) is providing Egyptian biopharmaceutical company Minapharm with up to $16.5 million (€14 million) to advance another vaccine candidate against … more ➔
NeurologyHow biotech is treating epilepsy beyond seizuresFor decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and … more ➔
clinical dataApollo vaccine triggers broad rhinovirus immunity in Phase 1UK biotech Apollo Therapeutics has reported early Phase 1 data showing that one dose of its experimental rhinovirus vaccine, APL-10456, induced immune responses recognizing all three rhinovirus species … more ➔
fundraisingImmatics adds $150M ahead of anzu-cel readoutGerman biotech Immatics is raising $150 million (€128.6 million) through an underwritten offering to strengthen its balance sheet ahead of a pivotal readout for its lead cancer cell therapy, anzu- … more ➔
startupsRevier launches with €6M to develop novel cardiometabolic approachHeidelberg-based Revier Therapeutics has raised €6 million in seed financing to develop selective class IIa histone deacetylase (HDAC) inhibitors for cardiometabolic diseases. more ➔
licensingRoche licenses Hanmi obesity drug for up to $2.3BRoche’s Genentech unit has licensed global rights outside South Korea to HM17321, Hanmi Pharm’s Phase 1 obesity candidate. The deal gives Hanmi $190 million (€163 million) upfront and could be … more ➔
financeHansa takes first step toward US Nasdaq listingSweden’s Hansa Biopharma has confidentially filed paperwork with the U.S. Securities and Exchange Commission for a potential initial public offering of American depositary shares. more ➔
PixelgenSpatial biologyProximity resolution: Swedish Pixelgen raises $15.5M to take cell architecture platform globalStockholm-based Pixelgen Technologies has raised $15.5 million in an oversubscribed Series B round to expand commercialization of its Proxiome platform. The Swedish company is targeting a gap in single-cell … more ➔
Pixelgen